62nd ASH Annual Meeting and Exposition: 635. Myeloproliferative Syndromes: Basic Science: Poster III

Oral and Poster Abstracts
Poster

AML, Anemias, Biological, HSCs, Animal models, Diseases, Non-Biological, chemical interactions, Therapies, Biological Processes, enzyme inhibitors, iron deficiency, MPN, Polycythemia vera, Cell Lineage, epigenetics, thrombocythemia, Study Population, Clinically relevant, Myeloid Malignancies, pharmacology, pathogenesis, pathways

3093

LSD1 Inhibitor CPI-482 Shows Efficacy and Prolongs Survival in Mouse Models of AML and Post-MPN AML in the Context of Constitutive JAK-STAT Pathway Activation

Raajit K. Rampal, MD, PhD¹, John P. McGrath, PhD²^*, Aishwarya Krishnan, BS³^*, Bing Li, MD³^*, Wenbin Xiao, MD, PhD⁴, David Nikom²^*, Jing Wang, PhD⁵^*, Ross L. Levine, MD^3,6,7 and Patrick Trojer, PhD⁵^*

¹Leukemia Service, Department of Medicine, Clinical Director, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Translational Sciences, Constellation Pharmaceuticals, Cambridge, MA
³Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Constellation Pharmaceuticals, Cambridge, MA
⁶Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

3094

Oncogenic SETBP1 Mutations Combine with Activating Mutations in CSF3R to Produce a Highly Proliferative, Lethal Leukemia through Aberrant Myc Signaling

Sarah A Carratt, PhD, BS¹, Theodore P. Braun, MD, PhD², Zachary Schonrock, BS¹^*, Brittany M. Smith²^*, Daniel J Coleman, PhD³^*, Garth Kong, MS³^*, Joseph Estabrook, MS³^*, Adrian Baris³^*, Lauren Maloney³^* and Julia E. Maxson, PhD²

¹Oregon Health & Science University, Portland, OR
²Knight Cancer Institute, Oregon Health & Science University, Portland, OR
³OHSU, Portland

3095

Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Yaoyu Chen^*, Matthew C. Stubbs, PhD^*, Michelle Pusey^*, Xiaoming Wen^*, Robert J. Collins^*, Kanishk Kapilashrami^*, Mark Rupar^*, Pramod Thekkat^*, Luping Lin, PhD^*, Kevin Bowman^*, Yan-ou Yang^*, Sharon Diamond^*, Swamy Yeleswaram, PhD, Sunkyu Kim^*, Holly K. Koblish, PhD^*, Yingnan Chen^* and Susan Wee, PhD, BS^*

Incyte Research Institute, Wilmington, DE

3096

Ifnα Attenuates the Disease Phenotype and Extends Survival in Mouse Models of MPN

Harini Nivarthi¹^*, Andrea Majoros, PhD²^*, Eva Hug, PhD²^*, Ruochen Jia, PhD³^*, Sarada Achyutuni⁴^*, Roland Jäger, PhD⁴^*, Raimund Holly¹^*, Beatrice Grabner⁵^*, Felix Rosebrock²^*, Shin-Jye Lee⁶^*, Chung-Wei Lee⁶^* and Robert Kralovics, PhD^4,7

¹CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
²MyeloPro Diagnostics and Research GmbH, Vienna, Austria
³MyeloPro Diagnostics and Research GmbH, Vienna, AUT
⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
⁵CeMM Research Center for Molecular Medicine, Vienna, AUT
⁶PharmaEssentia Co., Taipei, China
⁷CeMM Research Center For Molecular Medicine of the Austrian Academy of Sciences, Vienna, Wien, Austria

3097

Phenotyping of Disease-Initiating CD34⁺/CD38^─ Stem Cells in BCR-ABL1^─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Daniel Ivanov, MSc^1,2^*, Jelena D. Milosevic Feenstra¹^*, Gregor Eisenwort, MD, PhD^1,2^*, Robert Spörk, MSc¹^*, Alexandra Keller, PhD²^*, Barbara Peter^1,2^*, Michael Willmann^1,3^*, Georg Greiner^1,4^*, Gabriele Stefanzl^1,2^*, Katharina Slavnitsch^1,5^*, Gregor Hoermann^1,4,6, Sybille Hofer⁷^*, Wolfgang R. Sperr, MD^1,2^*, Heinz Sill, MD⁷^*, Peter Bettelheim, MD⁸^*, Klaus Geissler, MD⁹^*, Elisabeth Koller¹⁰^*, Michael Fillitz, MD¹¹^*, Michael Pfeilstocker, MD^1,10, Thomas Rülicke^1,5^*, Thamer Sliwa, MD¹⁰^*, Felix Keil, MD^1,10^*, Robert Kralovics, PhD^4,12 and Peter Valent, MD^1,2

¹Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
²Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
³Department for Companion Animals and Horses, Clinical Unit of Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria
⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
⁵Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria
⁶MLL Munich Leukemia Laboratory, Munich, Germany
⁷Department of Internal Medicine, Division of Hematology, Medical University of Graz, Graz, Austria
⁸Elisabethinen Hospital, Linz, Upper Austria, Austria
⁹5th Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria
¹⁰Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
¹¹Third Department of Internal Medicine, Hanusch Hospital, Vienna, Austria
¹²CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

3098

Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2^V617+ MPN Thrombosis

Angelica DaSilva, BS¹^*, Elena Aronovich, PhD²^*, Aithanh Nguyen³^*, Julia Nguyen⁴^*, David Reynolds⁵^*, Geneva D. Doak, B.S., PhD⁶^*, Gregory M. Vercellotti, MD⁴, David K. Wood, PhD⁶^* and Joan D. Beckman, MD, PhD²

¹University of Minnesota Twin Cities, Minneapolis, MN
²Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
³Vascular Biology Center, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Blaine, MN
⁴Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN
⁵Mechanical Enginering, Iowa State University, Ames, IA
⁶Biomedical Engineering, University of Minnesota, Minneapolis, MN

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH